Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 520.00
Bid: 520.00
Ask: 526.00
Change: 0.00 (0.00%)
Spread: 6.00 (1.154%)
Open: 522.00
High: 534.00
Low: 514.00
Prev. Close: 520.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Report

9 Jun 2015 07:00

RNS Number : 5628P
Gooch & Housego PLC
09 June 2015
 



 

For immediate release

9 June 2015

GOOCH & HOUSEGO PLC

INTERIM REPORT FOR THE SIX MONTHS ENDED 31 MARCH 2015

Gooch & Housego PLC (AIM:GHH) ("Gooch & Housego", "G&H", the "Company" or the "Group"), the specialist manufacturer of optical components and systems, today announces its interim results for the six months ended 31 March 2015.

Financial Highlights

Period ended 31 March

HY2015

HY2014

Change

Revenue

£38.9m

£34.4m

13.1%

Adjusted profit before tax1

£6.3m

£5.1m

23.5%

Adjusted basic earnings per share 1

19.3p

15.9p

21.4%

Interim dividend per share

3.0p

2.6p

15.4%

Net cash

£11.9m

£2.3m

£9.6m

Statutory profit before tax

£5.1m

£3.7m

37.8%

Basic earnings per share

15.6p

11.0p

41.8%

1 Adjusted for amortisation of acquired intangible assets, site closure costs, the impairment of goodwill and the gain on bargain purchase in relation to Spanoptic Limited.

Highlights

· Strong performance from industrial laser and telecommunications products

· Adjusted profit before tax up 23.5% from £5.1m to £6.3m

· Investment in R&D up 10%

· Melbourne site closure completed and products transferred to other G&H sites

· Net cash of £11.9 million at period end (2014: £2.3 million)

· Solid order book of £34.6 million, up 5.8% since 30 September 2014

· Performance improvement initiatives launched across G&H

· Interim dividend increased by 15% to 3.0p

 

Mark Webster, Chief Executive of Gooch & Housego PLC, commented on the results:

 "Gooch & Housego has performed well in the first six months of the financial year against a background of generally improving market conditions. We remain focused on delivering our financial goals through our twin strategies of diversification and moving up the value chain. The new management team has put in place a performance improvement programme prioritising operational excellence, business development and R&D; it is progressing well and will help underpin future performance."

For further information please contact:

Gooch & Housego PLC

Mark Webster / Andrew Boteler

01460 256 440

Buchanan

Mark Court / Gabriella Clinkard

020 7466 5000

Investec Bank plc (Nomad & Broker)

Patrick Robb / David Anderson

020 7597 4000

Operating and Financial Review

Performance Overview

In the six months to 31 March 2015, the business has once again delivered sales growth and improving margins driven by a strong performance in our Industrial division. In turn this has meant that profit growth is strong for the period. Net cash has grown from £8.7 million at the year end to £11.9 million as at 31 March 2015, in a six month period that has also seen Gooch & Housego invest in inventory ahead of the scheduled Palo Alto facility move to nearby Fremont and complete the closure of its Melbourne facility. Our strong balance sheet underpins the increase in our interim dividend by 15% and also reflects our confidence in the business.

REVENUE

Six months ended 31 March

2015

2014

£'000

% of total

£'000

% of total

Industrial

22,313

57%

18,917

55%

Aerospace and Defence

10,314

27%

10,218

30%

Life Sciences

4,317

11%

3,608

10%

Scientific Research

2,001

5%

1,679

5%

Group Revenue

38,945

100%

34,422

100%

Group revenue for the half year was £38.9 million, an increase of £4.5 million, or 13% over the comparative period last year. On a constant currency basis revenue was 10% higher.

In our Industrial segment, revenue was 18% up on the corresponding period last year. This has been driven by strong demand for both solid state and fibre optic lasers to service micro-electronic materials processing applications. Telecommunications has been the other major growth driver in industrials, with crystal production for modulation systems being supplemented by a surge in demand for under-sea telecommunications components.

Aerospace & Defence revenue was flat, following strong growth in recent years and continued strong sales of sub-assemblies for defence applications. Whilst sales of navigation components for the civil aerospace market remain buoyant, cost and price pressures have reduced margins for this particular product. We continue to remain optimistic about the growth potential for our core capabilities in this sector.

Life Sciences revenues were up 20% compared with the same period last year, driven mainly by an increase in demand for components for laser surgery and laser treatment applications.

The Scientific Research market performed well in the period, up 19%, albeit from a low comparison base. This was driven by demand for specialised crystal material used in nuclear fusion research.

Order intake in the first half of the year has been encouraging. The order book at 31 March 2015 was £34.6 million and the Company has booked £39.7 million in orders since 1 October 2014.

 

 

RECONCILIATION OF ADJUSTED PERFORMANCE MEASURES

 

Operating Profit

Net finance costs

Taxation

Earnings

per share

Half Year to 31 March

2015

£000

2014

£000

2015

£000

2014

£000

2015

£000

2014

£000

2015

pence

2014

pence

Reported

5,248

3,956

(148)

(293)

(1,363)

(1,031)

15.6

11.0

Amortisation of acquired intangible assets

802

775

-

-

(209)

(221)

2.5

2.3

Gain on bargain purchase

-

(1,039)

-

-

-

-

-

(4.4)

Impairment of goodwill

-

1,538

-

-

-

-

-

6.5

Restructuring costs

417

172

-

-

(108)

(58)

1.2

0.5

Adjusted

6,467

5,402

(148)

(293)

(1,680)

(1,310)

19.3

15.9

 

 

Adjusted profit before tax was £6.3 million, up 24% on the prior year (H1 2014: £5.1 million). This reflects the increased volume, particularly in the Industrial and Life Sciences markets.

 

 

Operational and Strategy Review

Products and Markets - Industrial

Gooch & Housego's principal industrial markets are industrial lasers, telecommunications, metrology, sensing and semiconductor manufacturing. Industrial lasers are used in a diverse range of precision material processing applications ranging from microelectronics to automotive.

Business in our industrial laser market was excellent in the first six months of the year, underpinned by good demand for our acousto-optic components for fibre lasers and solid state lasers. Sales of products into the industrial laser market in the six months to 31 March 2015, were 18% higher compared with the equivalent period last year.

The industrial laser market is continuing to evolve and grow, driven by the success of the fibre laser. Gooch & Housego anticipated these changes with the development of a family of products for fibre laser applications, including the Fibre-Q, with the result that the Company is now benefitting from these market trends. Recent innovations have enabled Gooch & Housego to keep up with the demanding requirements of this cost sensitive application, paving the way for greater market penetration. In other applications, most notably fibre-optic sensing, the Fibre-Q is proving to be a key enabling technology that is now being deployed by a number of our customers.

Whilst sales of products for fibre laser applications have been growing steadily, demand for the traditional acousto-optic Q-switch products remained solid, sales of which represented just 9% of our total business during the period under review. A consequence of these market dynamics is a consolidation in the variety of acousto-optic products required to meet customer needs. In response to these changes, and as a result of the steady improvements in productivity, the decision was made in 2014 to close the Melbourne, Florida, operation and to transfer the business to the Company's Ilminster, UK, and Palo Alto, California, facilities. This process is now complete. All product lines have now been transferred, the site has been closed and the property sold. The closure of the Melbourne site entailed a cash cost of $0.8 million and is expected to deliver annual cash savings of $1.0 million.

In telecommunications, sales of lithium niobate wafers for modulation applications continue to be a strong market. In 2015 this has been supplemented by strong demand for fibre optic components for under-sea telecommunications applications. As a result, the telecommunications market segment increased by 38% compared with the equivalent period last year.

Products and Markets - Aerospace and Defence

The Aerospace & Defence market for Gooch & Housego is characterised by high-value, long-term programmes involving the main US and European defence contractors. During the first six months of 2015, the Company has consolidated its position in the Aerospace & Defence market. Gooch & Housego's precision optics and acousto-optic technologies have contributed most to the Aerospace & Defence markets in the last six months, with navigation, range finding and target designation being the principal applications.

This sector was flat for Gooch and Housego during the first six months. With greater certainty and visibility on the US Defence budget and the adoption of technologies which play to Gooch & Housego's core capabilities, we believe there is strong growth potential for us going forward. Investment in this area has taken place.  

Products and Markets - Life Sciences

Gooch & Housego's three principal Life Sciences revenue streams are derived from diagnostics (fibre-optic modules for optical coherence tomography (OCT) applications), surgery / treatments (electro-optics and acousto-optics for lasers) and biomedical research (acousto-optics for microscopy applications). In each application area the Company is making steady progress in moving up the value chain and is currently selling sub-systems as well as components to several larger customers.

This market sector grew by 20% in the six months to 31 March 2015, compared with the equivalent period last year, driven mainly by an increase in demand for components for laser surgery and laser treatment applications.

The principal commercial application of OCT systems is retinal imaging, and Gooch & Housego continues to be the leading provider of fibre optic solutions (products and design services) to this industry. Gooch & Housego considers OCT to be a growth technology and is investing both in the development of new products and in keeping its current products cost competitive.

Products and Markets - Scientific Research

The key application in Scientific Research is laser inertial confinement fusion ("laser fusion"), where lasers are used to create the conditions found in the core of a star. In addition to pure research in high energy and plasma physics, these vast laser systems are being used to investigate whether this technology could provide clean, carbon-free energy to reduce dependency on fossil fuels. Gooch & Housego is continuing to supply crystals for new system construction and expects ongoing business to service replacement and maintenance requirements.

Strategy

Gooch & Housego has developed, and measures itself, on a set of strategies to deliver long term, sustainable growth for its shareholders. These can be categorised into two broad pillars: "Diversification" and, "Moving up the Value Chain". In seeking to achieve its strategic goals management evaluates these long term opportunities through short term strategies including investment in R&D to deliver organic growth, acquisitions, market focused business development and strategic partnerships.

R&D: In the first six months of the current financial year, Gooch & Housego invested £3.2 million in research & development. This represents 8.2% of revenue and is 10% higher than the same period last year (2014: £2.9m).

Diversification: Gooch & Housego seeks to develop, through R&D and acquisition, a presence in new markets that offer the potential for significant growth as a result of their adoption of photonic technology, whilst also reducing exposure to cyclicality in any particular sector. In the current period Gooch & Housego has grown its business in its core Industrial and Life Sciences markets. Moreover, the business has continued to invest in its quality systems and business development in order to strengthen its position in these markets in the future.

Moving up the Value Chain: Gooch & Housego seeks to move up the value chain to more complex sub-assemblies and systems through leveraging its excellence in materials and components, and by providing photonic design and engineering solutions for our customers. This will enable Gooch & Housego to transition from a components supplier to a solutions provider. A significant proportion of our business in the Aerospace & Defence market now comes from the sale of sub-systems rather than discrete components.

As well as continuing to develop a leadership position in space photonics, the STG is actively engaged in near-market developments in OCT, fibre lasers and fibre optic sensing as the Company leverages its components expertise to move up the value chain into systems.

Performance Improvement Programme

In addition to its two core strategies, in 2015 the business has identified three areas of focus as part of a performance improvement programme. These are: a) ensuring a consistent level of operational excellence across all sites, b) developing deeper ties with key target customers and c) ensuring we have a balanced R&D portfolio that meets the business's strategic goals. As part of this initiative the Companyis in the process of moving its Palo Alto site to nearby Fremont, which will provide improved facilities and room for further growth. The transfer is expected to be completed by the end of the financial year giving rise to a non-recurring cost of £0.9m.

Acquisitions

Gooch & Housego will continue to evaluate acquisition opportunities that have the potential to accelerate delivery of the Company's strategic objectives. Having established a presence in its target markets, Gooch & Housego is now focussing on moving up the value chain in each of those markets. Whilst the business will continue to evaluate bolt on businesses in our core component technologies, continued strong focus is being placed on acquisition opportunities that enhance the Company's ability to wrap electronics and software around core photonic products to yield system-level solutions.

Cash Flow and Financing

In the six months to 31 March 2015 Gooch & Housego generated cash from operations of £5.8 million, compared with £4.9 million in the same period of 2014. 2015 operating cash flows include a net cash outflow of £0.5 million relating to the closure of the Company's Melbourne, Florida, facility.

As part of the preparations for moving its Palo Alto site to nearby Fremont, the business is currently building inventory levels to satisfy expected customer requirements while the new facility is brought on line. The planned inventory build, together with the impact of exchange rates and positive trading patterns, have resulted in inventory levels increasing by £1.6 million to £16.3 million since the year end. It is expected that some of this additional inventory holding will unwind by the financial year end. Capital expenditure on property, plant and equipment was £1.1 million in the period (2014: £0.9 million). The main fixed asset additions were in relation to expanding our Torquay facilities and equipment to accommodate the Systems Technology Group.

Since 30 September 2014, the Company's net cash position has increased from £8.7 million to £11.9 million. On 14 November 2014, the Company re-financed its debt facilities with the Royal Bank of Scotland (RBS). Gooch & Housego now has a committed revolving credit facility of $15 million and an uncommitted flexible acquisition facility of $20 million available until 30 April 2019. Upon inception of the new facility, all existing RBS borrowings were repaid. At 31 March 2015, $8 million of the revolving credit facility was drawn.

Staff

The Company workforce increased from 644 at 30 September 2014 to 664 at the end of March 2015. This increase was largely due to recruitment of staff to support the Company's growth strategy.

Dividends

The Directors have declared an interim dividend of 3.0p per share (2014 : 2.6p per share), a 15.4% increase on the prior period, which is reflective of the Directors' confidence in the Company's long term growth prospects, strong balance sheet and healthy cash position. This will be payable on 20 July 2015 to shareholders on the register as at 26 June 2015.

Prospects and outlook

Against a background of positive market conditions Gooch & Housego is well placed to deliver continued growth in FY15 and beyond, through our twin strategies of diversification and moving up the value chain. These strategies will be supplemented by the performance improvement programme aimed at driving operational excellence, developing deeper ties with key customers and ensuring we have a balanced R&D portfolio. Finally, the business has the financial and management capacity to execute on acquisition opportunities as they arise.

 

Gareth Jones Mark Webster Andrew Boteler

Chairman Chief Executive Officer Chief Financial Officer

 

 

9 June 2015

Unaudited interim results for the 6 months ended 31 March 2015

 

Group Income Statement

Note

Half Year to31 Mar 2015(Unaudited)

Half Year to31 Mar 2014(Unaudited)

Full Year to

30 Sep 2014(Audited)

£'000

£'000

£'000

Revenue

5

38,945

34,422

 

70,056

Cost of revenue

(23,385)

(20,960)

(41,706)

Gross profit

15,560

13,462

28,350

Research and Development

(2,921)

(2,577)

(5,160)

Sales and Marketing

(2,687)

(2,301)

(4,498)

Administration

(5,723)

(5,179)

(10,026)

Other income and expenses

1,019

551

(271)

Operating profit

5

5,248

3,956

8,395

Net finance costs

(148)

(293)

(514)

Profit before income tax expense

5,100

3,663

7,881

Income tax expense

6

(1,363)

(1,031)

(2,482)

Profit for the period

3,737

2,632

5,399

Earnings per share

 

7

15.6p

11.0p

22.5p

 

Reconciliation of operating profit to adjusted operating profit:

Half Year to31 Mar 2015(Unaudited)

Half Year to31 Mar 2014(Unaudited)

Full Year to 30 Sep 2014(Audited)

£'000

£'000

£'000

Operating profit

5,248

3,956

8,395

Amortisation of acquired intangible assets

802

775

1,525

Restructuring costs

 

417

172

1,555

Gain on bargain purchase: Spanoptic Limited

-

(1,039)

(1,039)

Impairment of goodwill (including CDI closure)

-

1,538

1,538

Adjusted operating profit

6,467

5,402

11,974

 

Group Statement of Comprehensive Income

Half Year to31 Mar 2015(Unaudited)

Half Year to31 Mar 2014(Unaudited)

Full Year to 30 Sep 2014(Audited)

£'000

£'000

£'000

Profit for the period

3,737

2,632

5,399

Other comprehensive income

Fair value adjustment of interest rate swap net of tax

16

5

58

Currency translation difference

 

2,871

(837)

90

Other comprehensive income / (expense) for the period

 

2,887

(832)

148

Total comprehensive income for the period

6,624

1,800

5,547

Unaudited interim results for the 6 months ended 31 March 2015

 

Group Balance Sheet

31 Mar 2015(Unaudited)

31 Mar 2014(Unaudited)

30 Sep 2014(Audited)

£'000

£'000

£'000

Non-current assets

Property, plant and equipment

24,031

24,339

24,140

Intangible assets

21,312

20,697

20,668

Deferred income tax assets

2,797

3,462

3,114

48,140

48,498

47,922

Current assets

Inventories

16,304

13,976

14,663

Income tax assets

401

508

487

Trade and other receivables

15,690

14,106

13,005

Cash and cash equivalents

17,240

12,016

17,094

49,635

40,606

45,249

Current liabilities

Trade and other payables

(13,591)

(9,929)

(11,829)

Borrowings

(5,349)

(7,972)

(8,048)

Income tax liabilities

(96)

(131)

(244)

Provision for other liabilities and charges

(389)

(272)

(447)

(19,425)

(18,304)

(20,568)

Net current assets

30,210

22,302

24,681

Non-current liabilities

Borrowings

-

(1,698)

(360)

Deferred income tax liabilities

(2,478)

(2,536)

(2,306)

Derivative financial instruments

-

(32)

-

(2,478)

(4,266)

(2,666)

Net assets

75,872

66,534

69,937

Shareholders' equity

Capital and reservesattributable to equity shareholders

Called up share capital

4,812

4,760

4,774

Share premium account

15,515

15,420

15,420

Merger reserve

2,671

2,671

2,671

Hedging reserve

(5)

(74)

(21)

Cumulative translation reserve

2,101

(1,697)

(770)

Retained earnings

50,778

45,454

47,863

Equity Shareholders' Funds

75,872

66,534

69,937

 

Unaudited interim results for the 6 months ended 31 March 2015

 

Statement of Changes in Equity

Sharecapitalaccount£000

Sharepremiumaccount£000

Mergerreserve£000

 

Hedging

reserve£000

 

Retained

earnings£000

 

Total

equity

£000

 

At 1 October 2013

4,620

15,213

2,671

(79)

42,514

64,939

Profit for the period

-

-

-

-

2,632

2,632

Other comprehensive income for the period

-

-

-

5

(837)

(832)

Total comprehensive income for the period

-

-

-

5

1,795

1,800

Dividends

-

-

-

-

(950)

(950)

Proceeds from shares issued

140

207

-

-

(120)

227

Fair value of employee services

-

-

-

-

122

122

Tax credit relating to share option schemes

-

-

-

-

396

396

140

207

-

-

(552)

(205)

At 31 March 2014 (unaudited)

4,760

15,420

2,671

(74)

43,757

66,534

At 1 October 2014

4,774

15,420

2,671

(21)

47,093

69,937

Profit for the period

-

-

-

-

3,737

3,737

Other comprehensive income for the period

-

-

-

16

2,871

2,887

Total comprehensive income for the period

-

-

-

16

6,608

6,624

Dividends

-

-

-

-

(1,101)

(1,101)

Proceeds from shares issued

38

95

-

-

(35)

98

Fair value of employee services

-

-

-

-

220

220

Tax credit relating to share option schemes

-

-

-

-

94

94

38

95

-

-

(822)

(689)

At 31 March 2015 (unaudited)

4,812

15,515

2,671

(5)

52,879

75,872

 

Unaudited interim results for the 6 months ended 31 March 2015

 

Group Cash Flow Statement

Half Year to31 Mar 2015(Unaudited)

Half Year to31 Mar 2014(Unaudited)

Full Year to 30 Sep 2014(Audited)

£'000

£'000

£'000

Cash flows from operating activities

Cash generated from operations

5,771

4,905

15,298

Income tax paid

(692)

(582)

(1,625)

Net cash generated from operating activities

5,079

4,323

13,673

Cash flows from investing activities

Acquisition of subsidiaries (net of cash acquired)

-

(5,532)

(5,532)

Purchase of property, plant and equipment

(1,090)

(853)

(1,909)

Sale of property, plant and equipment

631

88

26

Purchase of intangible assets

(337)

(74)

(852)

Interest received

11

3

8

Net cash used in investing activities

(785)

(6,368)

(8,259)

Cash flows from financing activities

Drawdown of acquisition borrowing facility

5,168

4,971

4,832

Repayment of borrowings

(8,731)

(1,704)

(3,196)

Proceeds from issues of share capital

98

123

105

Dividends paid to ordinary shareholders

(1,101)

(950)

(1,569)

Interest paid

(178)

(230)

(569)

Net cash (used in) / generated by financing activities

(4,744)

2,210

(397)

Net (decrease) / increase in cash

(450)

165

5,017

Cash at beginning of the period

17,094

12,088

12,088

Exchange gains / (losses) on cash

596

(237)

(11)

Cash at the end of the period

17,240

12,016

17,094

 

 

Notes to the Group Cash Flow Statement

Half Year to31 Mar 2015(Unaudited)

Half Year to31 Mar 2014(Unaudited)

Full Year to

30 Sep 2014(Audited)

£'000

£'000

£'000

Profit before income tax

5,100

3,663

7,881

Adjustments for:

- Amortisation of acquired intangible assets

802

775

1,525

- Impairment of goodwill

-

1,538

1,538

- Gain on bargain purchase: Spanoptic Limited

-

(1,039)

(1,039)

- Amortisation of other intangible assets

88

79

164

- Depreciation

1,355

1,227

2,644

- Profit on disposal of property, plant

and equipment

-

25

21

- Share based payment obligations

220

122

361

- Finance income

(11)

(3)

(8)

- Finance costs

159

296

522

Total adjustments

2,613

3,020

5,728

Changes in working capital

- Inventories

(816)

(104)

(538)

- Trade and other receivables

(1,160)

493

2,097

- Trade and other payables

34

(2,167)

130

Total changes in working capital

(1,942)

(1,778)

1,689

Cash generated from operating activities

5,771

4,905

15,298

 

 

Reconciliation of net cash flow to movements in net cash

Half Year to31 Mar 2015(Unaudited)

Half Year to31 Mar 2014(Unaudited)

Full Year to

30 Sep 2014(Audited)

£'000

£'000

£'000

(Decrease) / increase in cash in the period

(450)

165

5,017

Borrowings

(5,168)

(4,971)

(4,832)

Repayment of borrowings

8,731

1,704

3,196

Changes in net cash resulting from cash flows

3,113

(3,102)

3,381

Finance leases acquired

-

(257)

(257)

Translation differences

92

(14)

(157)

Movement in net cash in the period / year

3,205

(3,373)

2,967

Net cash at start of period

8,686

5,719

5,719

Net cash at end of period

11,891

2,346

8,686

Analysis of net cash

At 1 Oct 2014

Cash flow

Exchange movement

Non-cash movement

At 31 Mar

2015

£'000

£'000

£'000

£'000

£'000

Cash at bank and in hand

17,094

(450)

596

-

17,240

Debt due within 1 year

(7,992)

3,193

(483)

-

(5,282)

Debt due after 1 year

(320)

341

(21)

-

-

Finance leases

(96)

29

-

-

(67)

Net cash

8,686

3,113

92

-

11,891

 

Notes to the Interim Report

 

1. Basis of Preparation

 

The unaudited Interim Report has been prepared under the historical cost convention and in accordance with International Financial Reporting Standards ("IFRS"), as adopted by the European Union.

 

The Interim Report was approved by the Board of Directors and the Audit Committee on 9 June 2015. The Interim Report does not constitute statutory financial statements within the meaning of the Companies Act 2006 and has not been audited.

 

Comparative figures in the Interim Report for the year ended 30 September 2014 have been taken from the Group's audited statutory financial statements on which the Group's auditors, PricewaterhouseCoopers LLP, expressed an unqualified opinion. The comparative figures to 31 March 2014 are unaudited.

 

The Interim Report will be announced to all shareholders on the London Stock Exchange and published on the Group's website on 9 June 2015. Copies will be available to members of the public upon application to the Company Secretary at Dowlish Ford, Ilminster, Somerset, TA19 0PF.

 

The accounting policies adopted are consistent with those of the annual financial statements for the year ended 30 September 2014, as described in those financial statements.

2. Application of IFRS

 

Adoption of new standards

 

During the current reporting period there were no new standards or amendments which had a material impact on the net assets of the Group. In addition, standards or amendments issued but not yet effective are not expected to have a material impact on the net assets of the Group. However, the Group is closely monitoring the IASB projects on Contract Revenue recognition and the Lease accounting overhaul as they could potentially have a material impact on the Group's results.

 

3. Estimates

 

The preparation of interim financial statements requires management to make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

 

In preparing these condensed consolidated interim financial statements, the significant judgments made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements for the year ended 30 September 2014.

 

4. Financial risk management

 

The Company's activities expose it to a variety of financial risks, market risk (including currency risk, cash flow interest rate risk and price risk), credit risk and liquidity risk.

 

The interim condensed consolidated financial statements do not include all financial risk management information and disclosures required in the annual financial statements and should be read in conjunction with the Company's annual financial statements as at 30 September 2014.

 

There have been no changes to the risk management policies since the year end.

 

5. Segmental analysis

Aerospace & Defence

Life Sciences

Industrial

Scientific Research

Corporate

Total

For half year to 31 March 2015

£'000

£'000

£'000

£'000

£'000

£'000

Revenue

Total revenue

10,314

4,317

25,421

2,001

-

42,053

Inter and intra-division

-

-

(3,108)

-

-

(3,108)

External revenue

10,314

4,317

22,313

2,001

-

38,945

Divisional expenses

(8,993)

(3,598)

(16,716)

(1,556)

(589)

(31,452)

EBITDA¹

1,321

719

5,597

445

(589)

7,493

EBITDA %

12.8%

16.7%

25.1%

22.2%

-

19.2%

Depreciation and Amortisation

(296)

(164)

(852)

(70)

(61)

(1,443)

Operating profit before amortisation of acquired intangible assets

1,025

555

4,745

375

(650)

6,050

Amortisation of acquired intangible assets

-

-

-

-

(802)

(802)

Operating profit

1,025

555

4,745

375

(1,452)

5,248

Operating profit margin %

9.9%

12.9%

21.3%

18.7%

-

13.5%

Aerospace & Defence

Life Sciences

Industrial

Scientific Research

Corporate

Total

For half year to 31 March 2014

£'000

£'000

£'000

£'000

£'000

£'000

Revenue

Total revenue

10,218

3,608

20,935

1,679

-

36,440

Inter and intra-division

-

-

(2,018)

-

-

(2,018)

External revenue

10,218

3,608

18,917

1,679

-

34,422

Divisional expenses

(8,460)

(3,023)

(14,591)

(1,592)

(222)

(27,888)

EBITDA¹

1,758

585

4,326

87

(222)

6,534

EBITDA %

17.2%

16.2%

22.9%

5.2%

-

19.0%

Depreciation and Amortisation

(286)

(129)

(765)

(45)

(79)

(1,304)

Operating profit before amortisation of acquired intangible assets and impairment of goodwill

1,472

456

3,561

42

(301)

5,230

Amortisation of acquired intangible assets and impairment of goodwill

-

-

-

-

(1,274)

(1,274)

Operating profit

1,472

456

3,561

42

(1,575)

3,956

Operating profit margin %

14.4%

12.6%

18.8%

2.5%

-

11.5%

¹EBITDA = Earnings before interest, tax, depreciation and amortisation.

All of the amounts recorded are in respect of continuing operations.

 

5. Segmental analysis continued

 

Analysis of revenue by destination

 

Half year to

31 Mar 2015

(Unaudited)

Half year to

31 Mar 2014

(Unaudited)

£'000

£'000

United Kingdom

7,400

6,807

America

17,144

14,604

Continental Europe

8,128

7,733

Asia-Pacific

6,273

5,278

38,945

34,422

 

 

 

6. Income tax expense

 

Analysis of tax charge in the period

Half Year to

31 Mar 2015(Unaudited)

Half Year to31 Mar 2014(Unaudited)

Full Year to 30 Sep 2014 (Audited)

£'000

£'000

£'000

Current taxation

UK Corporation tax

562

526

1,446

Overseas tax

380

404

630

Adjustments in respect of prior year tax charge

-

-

(165)

Total current tax

942

930

1,911

Deferred tax

Origination and reversal of temporary differences

421

101

49

Adjustments in respect of prior year deferred tax

-

-

504

Impact of tax rate change in 2013 to 20%

-

-

18

Total deferred tax

421

101

571

Income tax expense per income statement

1,363

1,031

2,482

 

The tax charge for the six months ended 30 March 2015 is based on the estimated effective rate of the tax for the Group for the full year to 30 September 2015. The estimated rate is applied to the profit before tax.

 

7. Earnings per share

 

The calculation of earnings per 20p Ordinary Share is based on the profit for the period using as a divisor the weighted average number of Ordinary Shares in issue during the period. The weighted average number of shares is given below.

 

Half Year to31 Mar 2015(Unaudited)

Half Year to31 Mar 2014(Unaudited)

Full Year to 30 Sep 2014(Audited)

No.

No.

No.

Number of shares used for basic earnings per share

24,041,328

23,864,426

23,984,536

Dilutive shares

373,847

125,595

213,581

Number of shares used for dilutive earnings per share

24,415,175

23,990,021

24,198,117

 

 

A reconciliation of the earnings used in the earnings per share calculation is set out below:

 

Half Year to31 Mar 2015 (Unaudited)

Half Year to31 Mar 2014(Unaudited)

Full Year to30 Sep 2014(Audited)

£'000

p pershare

£'000

p pershare

£'000

p pershare

Basic earnings per share

3,737

15.6p

2,632

11.0p

5,399

22.5p

Adjustments net of income tax expense:

Amortisation of acquired intangible assets

593

2.5p

554

2.3p

1,144

4.8p

Goodwill impairment

-

-

1,538

6.5p

1,538

6.4p

Gain on bargain purchase: Spanoptic Limited

-

-

(1,039)

(4.4)p

(1,039)

(4.3p)

Restructuring costs

309

1.2p

114

0.5p

1,467

6.2p

Total adjustments net of income tax expense

902

3.7p

1,167

4.9p

3,110

13.1p

Adjusted basic earnings per share

4,639

19.3p

3,799

15.9p

8,509

35.6p

 

Basic diluted earnings per share

3,737

15.3p

2,632

11.0p

5,399

22.3p

Adjusted diluted earnings per share

4,639

19.1p

3,799

15.8p

8,509

35.2p

 

Adjusted earnings per share before amortisation and adjustments has been shown because, in the opinion of the Directors, it more accurately reflects the trading performance of the Group.

 

 

8. Dividend

 

The Directors have declared an interim dividend of 3.0 pence per share for the half year ended 31 March 2015. This dividend has not been accounted for within the period to 31 March 2015 as it is yet to be paid.

 

Half Year to31 Mar 2015(Unaudited)

Half Year to31 Mar 2014(Unaudited)

Full Year to 30 Sep 2014(Audited)

£'000

£'000

£'000

Final 2014 dividend paid : 4.6p per share

1,101

-

-

2014 Interim dividend paid : 2.6p per share

-

-

619

Final 2013 dividend paid in 2014 : 4.0p per share

-

950

950

1,101

950

1,569

 

 

9. Borrowings

 

The group's banking facilities with the Royal Bank of Scotland comprise a committed revolving credit facility of $15m and an uncommitted flexible acquisition facility of $20m both available until 30 April 2019.

The revolving credit facility attracts an interest rate of between 0.9% and 1.8% above LIBOR dependent upon the Company's leverage ratio.

 

 

10. Called up share capital

 

2015

No.

2014

No.

2015

£'000

2014

£'000

Allotted, issued and fully paid

Ordinary share of 20p each

 

24,062,036

 

23,797,999

 

4,812

 

4,760

 

 

 

11. Derivative financial instruments

Half Year to31 Mar 2015 (Unaudited)

Half Year to31 Mar 2014 (Unaudited)

Full Year to30 Sep 2014(Audited)

£'000

£'000

£'000

Interest rate swap

7

96

27

Current liability portion

7

64

27

Non-current liability portion

-

32

-

7

96

27

 

The notional principal amount of the outstanding interest swap contract at 31 March 2015 was $2.25 million (2014: $6.75 million). The swap contract expired on 1 April 2015 and has not been renewed.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR SSFFIAFISEIM
Date   Source Headline
18th Mar 20242:36 pmRNSDivestment of EM4
29th Feb 20247:00 amRNSDirector/PDMR Shareholding
27th Feb 20243:26 pmRNSNotification of Major Holdings
22nd Feb 20244:07 pmRNSNotification of Major Holdings
21st Feb 202412:31 pmRNSResult of AGM
21st Feb 202410:28 amRNSDirector/PDMR Shareholding
21st Feb 20249:43 amRNSDirector/PDMR Shareholding
21st Feb 20247:00 amRNSAGM Trading Update
12th Jan 20247:00 amRNSAnnual Report and Notice of AGM
10th Jan 20247:00 amRNSGrant of LTIP Awards
9th Jan 202411:53 amRNSNotification of Major Holdings
8th Jan 20243:57 pmRNSNotification of Major Holdings
4th Jan 20243:20 pmRNSDirector/PDMR Shareholding
5th Dec 20237:00 amRNSResults for the year ended 30 September 2023
8th Nov 20237:00 amRNSNotification of Full Year Results
23rd Oct 20232:23 pmRNSHolding(s) in Company
3rd Oct 20237:00 amRNSFull Year Trading Update
2nd Oct 20232:44 pmRNSHolding(s) in Company
9th Aug 20236:15 pmRNSDirector/PDMR Shareholding
31st Jul 20238:22 amRNSHolding(s) in Company
21st Jul 202311:58 amRNSCompletion of Acquisition and Issue of Equity
19th Jul 20237:00 amRNSAcquisition of Artemis Optical
23rd Jun 20234:11 pmRNSHolding(s) in Company
21st Jun 202310:26 amRNSDirector/PDMR Shareholding
20th Jun 20236:00 pmRNSAcquisition of GS Optics
6th Jun 20237:00 amRNSInterim Results
23rd May 20237:00 amRNSNotification of Half Year Results
3rd May 20238:56 amRNSIssue of Equity
4th Apr 20237:00 amRNSHalf Year Trading Update
30th Mar 20239:33 amRNSHolding(s) in Company
15th Mar 202312:00 pmRNSAppointment of Non-Executive Director
3rd Mar 20234:37 pmRNSHolding(s) in Company
2nd Mar 20231:10 pmRNSHolding(s) in Company
1st Mar 20239:44 amRNSHolding(s) in Company
22nd Feb 20231:50 pmRNSResult of AGM
22nd Feb 20237:00 amRNSAGM Trading Update
8th Feb 202312:59 pmRNSHolding(s) in Company
9th Jan 202311:44 amRNSGrant of LTIP Awards
21st Dec 202210:02 amRNSPosting of Annual Report and Notice of AGM
20th Dec 202212:30 pmRNSDirector/PDMR Shareholding
6th Dec 20224:26 pmRNSDirector/PDMR Shareholding
6th Dec 20229:38 amRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSResults for the year ended 30 September 2022
25th Nov 20223:17 pmRNSHolding(s) in Company
23rd Nov 20224:27 pmRNSHolding(s) in Company
18th Nov 20222:20 pmRNSHolding(s) in Company
2nd Nov 20227:00 amRNSNotification of Full Year Results
27th Oct 202212:56 pmRNSHolding(s) in Company
18th Oct 20222:50 pmRNSHolding(s) in Company
26th Aug 20221:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.